GNbAC1: Phase IIa started

GeNeuro began a single-blind, placebo-controlled, Swiss Phase IIa trial to evaluate single ascending-doses of 2 or 6 mg/kg IV GNbAC1 in about 10 MS patients. The company is also planning a 6-month, re...